Back to top
more

Insmed (INSM)

(Delayed Data from NSDQ)

$95.80 USD

95.80
23,379,074

-2.65 (-2.69%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $96.14 +0.34 (0.35%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Aparajita Dutta headshot

Bet on These 3 Small-Cap ETFs to Ride the January Effect

by Aparajita Dutta

Small caps jump early in 2026, reviving the January Effect. ETFs like VTWO offer diversified exposure to potential seasonal and macro-driven gains.

Zacks Equity Research

INSM Stock Up 78% in 6 Months: Here's What You Need to Know

by Zacks Equity Research

Insmed shares surged on FDA and EU approvals of Brinsupri, strong uptake, and a growing pipeline which fueled optimism around its revenue outlook.

Zacks Equity Research

Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last?

by Zacks Equity Research

Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar

by Zacks Equity Research

Mineralys Therapeutics leads a biotech surge, with four drug stocks up over 50% in 2025 and catalysts lining up for more upside in 2026.

Kanishka Das headshot

4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow

by Kanishka Das

MLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.

Zacks Equity Research

INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset

by Zacks Equity Research

Insmed sinks nearly 20% after Brinsupri failed a phase IIb sinus study, while the company adds a new monoclonal antibody asset to expand its pipeline.

Zacks Equity Research

Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Amgen (AMGN) Up 8% Since Last Earnings Report?

by Zacks Equity Research

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri

by Zacks Equity Research

INSM climbs after the EU clears Brinsupri as the first approved treatment for NCFB, backed by phase III ASPEN and phase II WILLOW results.

Zacks Equity Research

Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake

by Zacks Equity Research

INSM shares jump 16% as Brinsupri's strong debut offset wider Q3 losses, lifting revenue 52% year over year.